Doctor's Bio
Robert O. Cotes, MD, is an Associate Professor at Emory University School of Medicine in the Department of Psychiatry and Behavioral Sciences.
He is Director of the Clinical & Research Program for Psychosis at Grady Health System, which comprises of two clinical programs:
- PSTAR Clinic (Persistent Symptoms: Treatment, Assessment and Recovery)
- Project ARROW (Achieving Recovery through Resilience, Optimism, and Wellness). The PSTAR Clinic provides evidence-based, recovery-oriented care for individuals with persistent symptoms of psychosis, specializing in the use of clozapine. Project ARROW is a coordinated specialty care team for people experiencing early psychosis, offering comprehensive, person-centered care using a multidisciplinary approach.
Dr. Cotes is an investigator for multiple research studies focused on treatment options for psychosis. His research focuses on clozapine and early psychosis.
Board Certifications
American Board of Psychiatry and Neurology
Affiliations
Emory
Education & Training
- Medical School: West Virginia University School of Medicine
- Residency: Dartmouth-Hitchcock Medical Center
Locations and Directions
Grady Memorial Hospital
Phone: (404) 616-1000
Location:
80 Jesse Hill Jr Drive SE
Atlanta, GA 30303
Publications
- Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics.
Varghese JS, Goldsmith DR, Cotes RO, Ravikumar V, Ali MK, Pasquel FJ
International journal of obesity (2005). 2025;
PMID: 40817129 - Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: consensus guidelines from a global Delphi panel.
Siskind D, Northwood K, Pillinger T, Chan S, Correll C, Cotes RO, Every-Palmer S, Hahn M, Howes OD, Kane JM, Kelly D, Korman N, Lappin J, Mena C, Myles N, McCutcheon RA,
The lancet. Psychiatry. 2025;
PMID: 40617246 - Enhancing social cognition in psychosis - the potential role of open dialogue.
Gariup M, Bergström T, Saliger K, Palanci JM, Cotes RO, Stoklosa JB, Seikkula J
Schizophrenia (Heidelberg, Germany). 2025;11(1):84.
PMID: 40473661 - FDA Eliminates the Clozapine REMS-What Comes Next?
Kelly DL, Kane JM, Love RC, Cotes RO
JAMA psychiatry. 2025;82(8):751-752.
PMID: 40465276 - Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes.
de Leon J, Baldessarini RJ, Balon R, Bilbily J, Caroff SN, Citrome L, Correll CU, Cotes RO, Davis JM, DeLisi LE, Faden J, Freudenreich O, Goldsmith DR, Gurrera R, Josiassen RC, Kane JM, Kelly DL, Keshavan MS, Laitman RS, Lam YWF, Leung JG, Love RC, McCollum B, McGrane IR, Meyer JM, Nasrallah HA, Nucifora FC, Rothschild AJ, Rubio JM, Sajatovic M, Sarpal DK, Schoretsanitis G, Shad M, Shelton C, Sher L, Singh B, Surya S, Zarzar TR, Sanz EJ, De Las Cuevas C
Journal of clinical psychopharmacology. ;45(3):197-218.
PMID: 40198784 - Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I: A Review of the Pharmacokinetic Literature and Proposed Changes.
de Leon J, Baldessarini RJ, Balon R, Bilbily J, Caroff SN, Citrome L, Correll CU, Cotes RO, Davis JM, DeLisi LE, Faden J, Freudenreich O, Goldsmith DR, Gurrera R, Josiassen RC, Kane JM, Kelly DL, Keshavan MS, Laitman RS, Lam YWF, Leung JG, Love RC, McCollum B, McGrane IR, Meyer J, Nasrallah HA, Nucifora FC, Rothschild AJ, Rubio JM, Sajatovic M, Sarpal DK, Schoretsanitis G, Shad M, Shelton C, Sher L, Singh B, Surya S, Zarzar TR, Sanz EJ, De Las Cuevas C
Journal of clinical psychopharmacology. ;45(3):179-196.
PMID: 40198781 - A model for timely dissemination of critical information: Clozapine toxicity during the COVID pandemic.
Gannon J, Chengappa KNR, Cotes RO, Leung JG, Frailey P, Piechowicz M, Kistler E, Nathaniel V, Eldredge C, Alessandro J, Clinebell K, Yabs M, Adair D, Zimmerman J
The mental health clinician. 2025;15(1):30-35.
PMID: 39974758 - Trends in Formulary Restrictions for Long-Acting Injectable Antipsychotic Medications Among Medicare Drug Plans, 2019-2023.
Bunting SR, Cotes RO, Gray K, Chalmers K, Nguyen TD
Psychiatric services (Washington, D.C.). 2025;76(6):606-610.
PMID: 39881599 - Clozapine's High Incidence of Ileus and Pneumonia Demand Better Clinical Strategies-How Do We Get There?
Chengappa KNR, Cotes RO
The American journal of psychiatry. 2024;181(10):851-853.
PMID: 39350622 - Postcrisis Follow-Up and Linkage to Community Services.
McClanahan A, Adams CN, Hackman AL, Cotes RO, Minkoff K
The Psychiatric clinics of North America. 2024;47(3):531-546.
PMID: 39122344
PLANNING
PREPARING FOR YOUR VISIT
Whether you’re a patient or you’re visiting one, a little planning beforehand can make your visit to Grady easier and more comfortable. Here, you’ll find everything you need to prepare for your visit, including an appointment checklist, admissions information, dining options, and much more.